Valneva Snares Pfizer For Lyme Disease Vaccine Pact
French Biotech Banks $130m Upfront
Executive Summary
Days after inking a COVID-19 collaboration with Dynavax, Valneva has linked up with Pfizer to drive its Lyme disease vaccine VLA15 towards Phase III trials.
You may also be interested in...
Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
Coronavirus Update: New Funding For Valneva, Scotland Looks At Long COVID
France's Valneva raises new funds to progress its inactivated vaccine, while Scotland launches a new study into 'long COVID', Takeda reports positive interim results from a Japanese trial with Moderna's mRNA vaccine, a setback for GC's plasma therapy, and Celltrion begins exporting a therapeutic antibody.
Valneva Spies Chance To Join Third Wave Of COVID-19 Vaccines
The company is hoping for strong efficacy from its inactivated vaccine, boosted by two adjuvants